Uses of an immunomodulatory protein (GMI) from Ganoderma microsporum
AssigneeMycomagic Biotechnology Co., Ltd.
InventorJiunn-Liang Ko
Life of this patent
Estimating the term…
Abstract
The invention provides a method for inhibiting EGF receptor activity comprising contacting an EGF receptor with an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof. Also provided is a method for treating invasion and metastasis of cancer cells, comprising administering an effective amount of an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof, to a subject in need of such treatment.
Claims10
A method for inhibiting EGF receptor activity in lung cancer cells comprising contacting an EGF receptor with a pharmaceutical composition wherein the pharmaceutical composition comprises GMI or a recombinant thereof and an anti-cancer agent, wherein the GMI and the anti-cancer agent are in a synergistic amount in inhibiting EGF receptor in lung cancer cells, and wherein GMI has the amino acid sequences of:
- (1)-Leu-Ala-Trp-Asn-Val-Lys-(LAWNVK;
- SEQ ID NO:1) and (2)-Asp-Leu-Gly-Val-Arg-Pro-Ser-Tyr-Ala-Val-(DLGVRPSYAV;
- SEQ ID NO:2) or the amino acid sequence of MSDTALIFTLAWNVKQLAFDYTPNWGRGRPSSFIDTVTFPTVLTDKAYTYRVVVSGKD LGVRPSYAVESDGSQKINFLEYNSGYGIADTNTIQVYVIDPDTGNNFIVAQWN (SEQ ID NO:3), and wherein the anti-cancer agent is cisplatin.
A method for treating lung cancer and/or inhibiting invasion and metastasis of lung cancer cells comprising administering an effective amount of a pharmaceutical composition to a subject in need of such treatment;
- wherein the pharmaceutical composition comprises GMI or a recombinant thereof and an anti-cancer agent, wherein the GMI and the anti-cancer agent are in a synergistic amount in treating lung cancer and/or inhibiting invasion and metastasis of lung cancer cells, and wherein GMI has the amino acid sequences of:
- (1)-Leu-Ala-Trp-Asn-Val-Lys-(LAWNVK;
- SEQ ID NO:1) and (2)-Asp-Leu-Gly-Val-Arg-Pro-Ser-Tyr-Ala-Val-(DLGVRPSYAV;
- SEQ ID NO:2) or the amino acid sequence of:
- MSDTALIFTLAWNVKQLAFDYTPNWGRGRPSSFIDTVTFPTVLTDKAYTYRVVVSG KDLGVRPSYAVESDGSQKINFLEYNSGYGIADTNTIQVYVIDPDTGNNFIVAQWN (SEQ ID NO:3), and wherein the anti-cancer agent is cisplatin.
A pharmaceutical composition, comprising GMI or a recombinant thereof and an anti-cancer agent, wherein the GMI and the anti-cancer agent are in a synergistic amount in inhibiting EGF receptor and/or treating lung cancer and/or inhibiting invasion and metastasis of lung cancer cells, and wherein GMI has the amino acid sequences of:
- (1)-Leu-Ala-Trp-Asn-Val-Lys-(LAWNVK;
- SEQ ID NO:1) and (2)-Asp-Leu-Gly-Val-Arg-Pro-Ser-Tyr-Ala-Val-(DLGVRPSYAV;
- SEQ ID NO:2) or the amino acid sequence of MSDTALIFTLAWNVKQLAFDYTPNWGRGRPSSFIDTVTFPTVLTDKAYTYRVVVSGKD LGVRPSYAVESDGSQKINFLEYNSGYGIADTNTIQVYVIDPDTGNNFIVAQWN (SEQ ID NO:3), and wherein the anti-cancer agent is cisplatin.
Dependencies are inferred from the claim text.